SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Fennec Pharmaceuticals Inc. (FENC) Q3 Sales Rise 56% to $19.4M

Fennec reported Q3 2026 net product sales of $19.4M, up 56% year over year, and non-GAAP adjusted EBITDA of $5.8M. Cash from operations was $6.7M, and quarter-end cash was $48.7M.Material DetailsContext by AI AnalystThis is a commercial-stage growth update, with reported year-over-year product-sale…

FENC

Related stories